These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 7896956)

  • 21. Trypanosoma cruzi infection does not impair major histocompatibility complex class I presentation of antigen to cytotoxic T lymphocytes.
    Buckner FS; Wipke BT; Van Voorhis WC
    Eur J Immunol; 1997 Oct; 27(10):2541-8. PubMed ID: 9368608
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bacteria-specific T cells response. What role for HLA molecules?
    Breban M
    Rev Rhum Engl Ed; 1999 Jan; 66(1 Suppl):37S-39S. PubMed ID: 10063523
    [No Abstract]   [Full Text] [Related]  

  • 23. Pathways of antigen processing and presentation.
    Watts C; Powis S
    Rev Immunogenet; 1999; 1(1):60-74. PubMed ID: 11256573
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells.
    Lapointe R; Bellemare-Pelletier A; Housseau F; Thibodeau J; Hwu P
    Cancer Res; 2003 Jun; 63(11):2836-43. PubMed ID: 12782589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Artificial antigen-presenting cells expressing HLA class II molecules as an effective tool for amplifying human specific memory CD4(+) T cells.
    Garnier A; Hamieh M; Drouet A; Leprince J; Vivien D; Frébourg T; Le Mauff B; Latouche JB; Toutirais O
    Immunol Cell Biol; 2016 Aug; 94(7):662-72. PubMed ID: 26924643
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [MHC tetramers: tracking specific immunity].
    Kosor E; Gagro A; Drazenović V; Kuzman I; Jeren T; Rakusić S; Rabatić S; Markotić A; Gotovac K; Sabioncello A; Cecuk E; Kerhin-Brkljacić V; Gjenero-Margan I; Kaić B; Mlinarić-Galinović G; Kastelan A; Dekaris D
    Acta Med Croatica; 2003; 57(4):255-9. PubMed ID: 14639858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Viral and bacterial minigene products are presented by MHC class I molecules with similar efficiencies.
    Wolf BJ; Princiotta MF
    Mol Immunol; 2011 Jan; 48(4):463-71. PubMed ID: 21067810
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of MHC class I presentation of exogenous antigen by dendritic cells is controlled by CD4+ T cells engaging class II molecules in cholesterol-rich domains.
    Machy P; Serre K; Baillet M; Leserman L
    J Immunol; 2002 Feb; 168(3):1172-80. PubMed ID: 11801652
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bacterial heat shock proteins promote CD91-dependent class I MHC cross-presentation of chaperoned peptide to CD8+ T cells by cytosolic mechanisms in dendritic cells versus vacuolar mechanisms in macrophages.
    Tobian AA; Canaday DH; Boom WH; Harding CV
    J Immunol; 2004 May; 172(9):5277-86. PubMed ID: 15100266
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Presentation of native TROP-2 tumor antigens to human cytotoxic T lymphocytes by engineered antigen-presenting cells.
    Mangino G; Grazia Capri M; Barnaba V; Alberti S
    Int J Cancer; 2002 Oct; 101(4):353-9. PubMed ID: 12209960
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dendritic cells, but not macrophages or B cells, activate major histocompatibility complex class II-restricted CD4+ T cells upon immune-complex uptake in vivo.
    de Jong JM; Schuurhuis DH; Ioan-Facsinay A; Welling MM; Camps MG; van der Voort EI; Huizinga TW; Ossendorp F; Verbeek JS; Toes RE
    Immunology; 2006 Dec; 119(4):499-506. PubMed ID: 16995881
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Class I MHC presentation of exogenous antigens.
    Harding CV
    J Clin Immunol; 1996 Mar; 16(2):90-6. PubMed ID: 8690777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Loading of MHC class I and II presentation pathways by exogenous antigens: a quantitative in vivo comparison.
    Storni T; Bachmann MF
    J Immunol; 2004 May; 172(10):6129-35. PubMed ID: 15128799
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Superantigens are presented by and activate thymocytes from infants.
    Thulesen S; Jørgensen A; Gerwien J; Dohlsten M; Holst Nissen M; Odum N; Röpke C
    Exp Clin Immunogenet; 1999; 16(4):226-33. PubMed ID: 10575276
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of mRNA translation in direct MHC class I antigen presentation.
    Apcher S; Manoury B; Fåhraeus R
    Curr Opin Immunol; 2012 Feb; 24(1):71-6. PubMed ID: 22341517
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Presentation of a self-peptide for in vivo tolerance induction of CD4+ T cells is governed by a processing factor that maps to the class II region of the major histocompatibility complex locus.
    Fedoseyeva EV; Tam RC; Orr PL; Garovoy MR; Benichou G
    J Exp Med; 1995 Nov; 182(5):1481-91. PubMed ID: 7595218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antigen processing for MHC class I restricted presentation of exogenous influenza A virus nucleoprotein by B-lymphoblastoid cells.
    Voeten JT; Rimmelzwaan GF; Nieuwkoop NJ; Fouchier RA; Osterhaus AD
    Clin Exp Immunol; 2001 Sep; 125(3):423-31. PubMed ID: 11531950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The cross-priming pathway: a portrait of an intricate immune system.
    Basta S; Alatery A
    Scand J Immunol; 2007 Apr; 65(4):311-9. PubMed ID: 17386021
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heparan sulfates targeting increases MHC class I- and MHC class II-restricted antigen presentation and CD8(+) T-cell response.
    Knittel D; Gadzinski A; Hua S; Denizeau J; Savatier A; de la Rochère P; Boulain JC; Amigorena S; Piaggio E; Sedlik C; Léonetti M
    Vaccine; 2016 Jun; 34(27):3093-3101. PubMed ID: 27154391
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SV-BR-1-GM, a Clinically Effective GM-CSF-Secreting Breast Cancer Cell Line, Expresses an Immune Signature and Directly Activates CD4
    Lacher MD; Bauer G; Fury B; Graeve S; Fledderman EL; Petrie TD; Coleal-Bergum DP; Hackett T; Perotti NH; Kong YY; Kwok WW; Wagner JP; Wiseman CL; Williams WV
    Front Immunol; 2018; 9():776. PubMed ID: 29867922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.